115 related articles for article (PubMed ID: 27199202)
1. Pharmacokinetic investigations of the marker active metabolites 4-methylamino-antipyrine and 4-amino-antipyrine after intramuscular injection of metamizole in healthy piglets.
Burmańczuk A; Kowalski C; Giorgi M; Owen H; Grabowski T
J Vet Pharmacol Ther; 2016 Dec; 39(6):616-620. PubMed ID: 27199202
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic profiles of the active metamizole metabolites after four different routes of administration in healthy dogs.
Giorgi M; Łebkowska-Wieruszewska B; Lisowski A; Owen H; Poapolathep A; Kim TW; De Vito V
J Vet Pharmacol Ther; 2018 Jun; 41(3):428-436. PubMed ID: 29352476
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic profiles of the active metamizole metabolites in healthy horses.
Giorgi M; Aupanun S; Lee HK; Poapolathep A; Rychshanova R; Vullo C; Faillace V; Laus F
J Vet Pharmacol Ther; 2017 Apr; 40(2):165-171. PubMed ID: 27477925
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic profiles of the two major active metabolites of metamizole (dipyrone) in cats following three different routes of administration.
Lebkowska-Wieruszewska B; Kim TW; Chea B; Owen H; Poapolathep A; Giorgi M
J Vet Pharmacol Ther; 2018 Apr; 41(2):334-339. PubMed ID: 29164623
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic profiles of the two major active metabolites of metamizole, 4-methylaminoantipyrine (MAA) and 4-aminoantipyrine (AA), after intravenous injection in cats.
de Paula VV; Araújo-Silva G; Fernandes NS; Mouta AN; Nunes TL; de Paiva ALC; de Macêdo LB; Arcoverde KN; Urizar JTP
Res Vet Sci; 2023 Feb; 155():156-160. PubMed ID: 36701839
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic Profiles of Metamizole Metabolites after Intramuscular and Intravenous Administration in Healthy Arabian Horses.
Yılmaz İ; Maraş Z; Uğur Y; Erkan Özgür M; Durmaz M; İbrahim Ulusoy H; Erdoğan S
J Vet Pharmacol Ther; 2021 Nov; 44(6):927-936. PubMed ID: 34431528
[TBL] [Abstract][Full Text] [Related]
7. Impairment of the metabolism of dipyrone in asymptomatic carriers of the hepatitis-B virus does not occur in rapid acetylators.
Levy M; Safadi R; Zylber-Katz E; Granit L; Caraco Y
Eur J Clin Pharmacol; 2001 Sep; 57(6-7):461-5. PubMed ID: 11699610
[TBL] [Abstract][Full Text] [Related]
8. Formation and excretion of dipyrone metabolites in man.
Zylber-Katz E; Granit L; Levy M
Eur J Clin Pharmacol; 1992; 42(2):187-91. PubMed ID: 1618251
[TBL] [Abstract][Full Text] [Related]
9. Validity of saliva samples for the estimation of dipyrone metabolites pharmacokinetics.
Caraco Y; Zylber-Katz E; Granit L; Levy M
Arzneimittelforschung; 1993 Nov; 43(11):1204-8. PubMed ID: 8292065
[TBL] [Abstract][Full Text] [Related]
10. Dipyrone metabolite 4-MAA induces hypothermia and inhibits PGE2 -dependent and -independent fever while 4-AA only blocks PGE2 -dependent fever.
Malvar Ddo C; Aguiar FA; Vaz Ade L; Assis DC; de Melo MC; Jabor VA; Kalapothakis E; Ferreira SH; Clososki GC; de Souza GE
Br J Pharmacol; 2014 Aug; 171(15):3666-79. PubMed ID: 24712707
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic profiles of metamizole (dipyrone) active metabolites in goats and its residues in milk.
Kim TW; Łebkowska-Wieruszewska B; Sitovs A; Poapolathep A; Owen H; Lisowski A; Abilova Z; Giorgi M
J Vet Pharmacol Ther; 2018 Oct; 41(5):699-705. PubMed ID: 29943417
[TBL] [Abstract][Full Text] [Related]
12. Clinical pharmacokinetics of dipyrone and its metabolites.
Levy M; Zylber-Katz E; Rosenkranz B
Clin Pharmacokinet; 1995 Mar; 28(3):216-34. PubMed ID: 7758252
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of metamizol metabolites in healthy subjects after a single oral dose of metamizol sodium.
Vlahov V; Badian M; Verho M; Bacracheva N
Eur J Clin Pharmacol; 1990; 38(1):61-5. PubMed ID: 2328750
[TBL] [Abstract][Full Text] [Related]
14. Effect of cimetidine on the pharmacokinetics of the metabolites of metamizol.
Bacracheva N; Tyutyulkova N; Drenska A; Gorantcheva J; Schinzel S; Scholl T; Stoinov A; Tchakarski I; Tentcheva J; Vlahov V
Int J Clin Pharmacol Ther; 1997 Jul; 35(7):275-81. PubMed ID: 9247840
[TBL] [Abstract][Full Text] [Related]
15. Comparative bioavailability of two oral metamizole formulations. Influence of the acetylation phenotype.
Bacracheva N; Drenska A; Gorantcheva J; Tyutyulkova N; Vlahov V
Arzneimittelforschung; 1995 Mar; 45(3):282-5. PubMed ID: 7741785
[TBL] [Abstract][Full Text] [Related]
16. Determination of antipyrine metabolites in human plasma by solid-phase extraction and micellar liquid chromatography.
Carretero I; Vadillo JM; Laserna JJ
Analyst; 1995 Jun; 120(6):1729-32. PubMed ID: 7604956
[TBL] [Abstract][Full Text] [Related]
17. Plasma kinetics of dipyrone metabolites in rapid and slow acetylators.
Levy M; Flusser D; Zylber-Katz E; Granit L
Eur J Clin Pharmacol; 1984; 27(4):453-8. PubMed ID: 6519153
[TBL] [Abstract][Full Text] [Related]
18. Pyrazolones metabolites are relevant for identifying selective anaphylaxis to metamizole.
Ariza A; García-Martín E; Salas M; Montañez MI; Mayorga C; Blanca-Lopez N; Andreu I; Perkins J; Blanca M; Agúndez JA; Torres MJ
Sci Rep; 2016 Mar; 6():23845. PubMed ID: 27030298
[TBL] [Abstract][Full Text] [Related]
19. Dose-dependent pharmacokinetics of metabolites of dipyrone in saliva.
Neddermann E; Rohdewald P
Eur J Drug Metab Pharmacokinet; 1988; 13(2):105-11. PubMed ID: 3208789
[TBL] [Abstract][Full Text] [Related]
20. Quantification of 4-methylaminoantipyrine, the active metabolite of dipyrone, in human plasma.
Ojha A; Rathod R; Padh H
Bioanalysis; 2009 May; 1(2):293-8. PubMed ID: 21083168
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
